questionsmedicales.fr
Facteurs biologiques
Antigènes
Antigènes de surface
Complexe antigénique L1 leucocytaire
Complexe antigénique L1 leucocytaire : Questions médicales fréquentes
Diagnostic
5
Anticorps
Tests immunologiques
Cytométrie en flux
Anticorps monoclonaux
Maladies auto-immunes
Hématologie
Symptômes
5
Éruption cutanée
Immunité
Infections pulmonaires
Respiration
Symptômes neurologiques
Auto-immunité
Prévention
5
Prévention
Mode de vie sain
Examens médicaux
Détection précoce
Alimentation
Système immunitaire
Traitements
5
Immunosuppresseurs
Thérapies ciblées
Thérapie génique
Recherche
Corticostéroïdes
Inflammation
Essais cliniques
Traitements expérimentaux
Antibiotiques
Soins de soutien
Complications
5
Complications
Troubles auto-immuns
Cancers
Anomalies immunitaires
Complications neurologiques
Neuropathies
Complications cardiovasculaires
Inflammation chronique
Suivi médical
Traitements
Facteurs de risque
5
Facteurs de risque
Antécédents familiaux
Stress
Système immunitaire
Maladies auto-immunes
Risque accru
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Complexe antigénique L1 leucocytaire : Questions médicales les plus fréquentes",
"headline": "Complexe antigénique L1 leucocytaire : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Complexe antigénique L1 leucocytaire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-06",
"dateModified": "2026-03-28",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Complexe antigénique L1 leucocytaire"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Antigènes de surface",
"url": "https://questionsmedicales.fr/mesh/D000954",
"about": {
"@type": "MedicalCondition",
"name": "Antigènes de surface",
"code": {
"@type": "MedicalCode",
"code": "D000954",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.050.301"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Calgranuline A",
"alternateName": "Calgranulin A",
"url": "https://questionsmedicales.fr/mesh/D040501",
"about": {
"@type": "MedicalCondition",
"name": "Calgranuline A",
"code": {
"@type": "MedicalCode",
"code": "D040501",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.050.301.562.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Calgranuline B",
"alternateName": "Calgranulin B",
"url": "https://questionsmedicales.fr/mesh/D040502",
"about": {
"@type": "MedicalCondition",
"name": "Calgranuline B",
"code": {
"@type": "MedicalCode",
"code": "D040502",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.050.301.562.200"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Complexe antigénique L1 leucocytaire",
"alternateName": "Leukocyte L1 Antigen Complex",
"code": {
"@type": "MedicalCode",
"code": "D039841",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Lisa M James",
"url": "https://questionsmedicales.fr/author/Lisa%20M%20James",
"affiliation": {
"@type": "Organization",
"name": "The HLA Research Group, Department of Veterans Affairs Health Care System, Brain Sciences Center, Minneapolis VAMC, One Veterans Drive, Minneapolis, MN, 55417, USA."
}
},
{
"@type": "Person",
"name": "Apostolos P Georgopoulos",
"url": "https://questionsmedicales.fr/author/Apostolos%20P%20Georgopoulos",
"affiliation": {
"@type": "Organization",
"name": "The HLA Research Group, Department of Veterans Affairs Health Care System, Brain Sciences Center, Minneapolis VAMC, One Veterans Drive, Minneapolis, MN, 55417, USA. omega@umn.edu."
}
},
{
"@type": "Person",
"name": "Dylan Thibaut",
"url": "https://questionsmedicales.fr/author/Dylan%20Thibaut",
"affiliation": {
"@type": "Organization",
"name": "Medicine, Lake Erie College of Osteopathic Medicine (LECOM), Bradenton, USA."
}
},
{
"@type": "Person",
"name": "Sabine E Hammer",
"url": "https://questionsmedicales.fr/author/Sabine%20E%20Hammer",
"affiliation": {
"@type": "Organization",
"name": "Institute of Immunology, Department of Pathobiology, University of Veterinary Medicine Vienna, A-1210 Vienna, Austria."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Human leukocyte antigen-G in gynaecological tumours.",
"datePublished": "2023-07-06",
"url": "https://questionsmedicales.fr/article/37415092",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/iji.12626"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prediction of KIR3DL1/Human Leukocyte Antigen binding.",
"datePublished": "2024-05-05",
"url": "https://questionsmedicales.fr/article/38746109",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1101/2024.05.03.592082"
}
},
{
"@type": "ScholarlyArticle",
"name": "Association of Human Leukocyte Antigen (HLA) class II (",
"datePublished": "2023-06-22",
"url": "https://questionsmedicales.fr/article/37426636",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1178546"
}
},
{
"@type": "ScholarlyArticle",
"name": "Role of the Killer Immunoglobulin-like Receptor and Human Leukocyte Antigen I Complex Polymorphisms in Kaposi Sarcoma-Associated Herpesvirus Infection.",
"datePublished": "2023-08-18",
"url": "https://questionsmedicales.fr/article/37636520",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1093/ofid/ofad435"
}
},
{
"@type": "ScholarlyArticle",
"name": "Repeated human leukocyte antigens eplets, importance of typing the partner.",
"datePublished": "2024-05-08",
"url": "https://questionsmedicales.fr/article/38729449",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.trim.2024.102049"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Antigènes",
"item": "https://questionsmedicales.fr/mesh/D000941"
},
{
"@type": "ListItem",
"position": 4,
"name": "Antigènes de surface",
"item": "https://questionsmedicales.fr/mesh/D000954"
},
{
"@type": "ListItem",
"position": 5,
"name": "Complexe antigénique L1 leucocytaire",
"item": "https://questionsmedicales.fr/mesh/D039841"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Complexe antigénique L1 leucocytaire - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Complexe antigénique L1 leucocytaire",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Complexe antigénique L1 leucocytaire",
"description": "Comment diagnostiquer une anomalie du complexe L1 ?\nQuels tests sont utilisés pour le complexe L1 ?\nLe complexe L1 est-il lié à des maladies spécifiques ?\nPeut-on détecter le complexe L1 par biopsie ?\nQuels marqueurs sont associés au complexe L1 ?",
"url": "https://questionsmedicales.fr/mesh/D039841#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Complexe antigénique L1 leucocytaire",
"description": "Quels symptômes sont liés à des anomalies du complexe L1 ?\nLes anomalies du complexe L1 provoquent-elles des douleurs ?\nY a-t-il des symptômes cutanés associés ?\nLes anomalies du complexe L1 affectent-elles la respiration ?\nDes symptômes neurologiques peuvent-ils apparaître ?",
"url": "https://questionsmedicales.fr/mesh/D039841#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Complexe antigénique L1 leucocytaire",
"description": "Peut-on prévenir les anomalies du complexe L1 ?\nY a-t-il des vaccins pour prévenir les infections associées ?\nComment réduire le risque d'infections ?\nLes examens réguliers aident-ils à la prévention ?\nL'alimentation influence-t-elle le complexe L1 ?",
"url": "https://questionsmedicales.fr/mesh/D039841#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Complexe antigénique L1 leucocytaire",
"description": "Quels traitements sont disponibles pour les anomalies du complexe L1 ?\nLa thérapie génique est-elle une option ?\nLes corticostéroïdes sont-ils efficaces ?\nY a-t-il des traitements expérimentaux ?\nComment gérer les infections liées au complexe L1 ?",
"url": "https://questionsmedicales.fr/mesh/D039841#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Complexe antigénique L1 leucocytaire",
"description": "Quelles complications peuvent survenir avec le complexe L1 ?\nLes anomalies du complexe L1 peuvent-elles causer des cancers ?\nY a-t-il des complications neurologiques possibles ?\nLes complications cardiovasculaires sont-elles possibles ?\nComment gérer les complications liées au complexe L1 ?",
"url": "https://questionsmedicales.fr/mesh/D039841#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Complexe antigénique L1 leucocytaire",
"description": "Quels sont les facteurs de risque pour les anomalies du complexe L1 ?\nL'âge influence-t-il le risque d'anomalies L1 ?\nLe stress a-t-il un impact sur le complexe L1 ?\nLes maladies auto-immunes augmentent-elles le risque ?\nL'exposition à des toxines influence-t-elle le risque ?",
"url": "https://questionsmedicales.fr/mesh/D039841#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie du complexe L1 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des analyses immunologiques sont utilisés pour détecter des anomalies."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le complexe L1 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de cytométrie en flux et les tests d'anticorps spécifiques sont courants."
}
},
{
"@type": "Question",
"name": "Le complexe L1 est-il lié à des maladies spécifiques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est associé à certaines maladies auto-immunes et hématologiques."
}
},
{
"@type": "Question",
"name": "Peut-on détecter le complexe L1 par biopsie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une biopsie peut être réalisée pour évaluer l'expression du complexe L1 dans les tissus."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont associés au complexe L1 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs comme CD11a et CD18 sont souvent associés au complexe L1."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à des anomalies du complexe L1 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure fatigue, infections récurrentes et anomalies sanguines."
}
},
{
"@type": "Question",
"name": "Les anomalies du complexe L1 provoquent-elles des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent entraîner des douleurs dues à des inflammations ou des infections."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cutanés associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des éruptions cutanées peuvent survenir dans certains cas d'anomalies immunitaires."
}
},
{
"@type": "Question",
"name": "Les anomalies du complexe L1 affectent-elles la respiration ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent affecter la respiration si des infections pulmonaires se développent."
}
},
{
"@type": "Question",
"name": "Des symptômes neurologiques peuvent-ils apparaître ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes neurologiques peuvent survenir en cas d'atteinte auto-immune."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les anomalies du complexe L1 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un mode de vie sain peut aider à renforcer l'immunité."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins pour prévenir les infections associées ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des vaccins peuvent prévenir certaines infections, mais pas spécifiquement liées au complexe L1."
}
},
{
"@type": "Question",
"name": "Comment réduire le risque d'infections ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir une bonne hygiène et éviter les contacts avec des personnes malades peut aider."
}
},
{
"@type": "Question",
"name": "Les examens réguliers aident-ils à la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens réguliers peuvent aider à détecter précocement des anomalies immunitaires."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle le complexe L1 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut soutenir le système immunitaire et réduire les risques."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les anomalies du complexe L1 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des immunosuppresseurs et des thérapies ciblées."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en recherche, mais pas encore largement utilisée pour ce complexe."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes sont-ils efficaces ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les corticostéroïdes peuvent réduire l'inflammation associée aux anomalies du complexe L1."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements expérimentaux sont en cours d'évaluation dans des essais cliniques."
}
},
{
"@type": "Question",
"name": "Comment gérer les infections liées au complexe L1 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les infections sont traitées avec des antibiotiques et des soins de soutien appropriés."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le complexe L1 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des infections graves et des troubles auto-immuns."
}
},
{
"@type": "Question",
"name": "Les anomalies du complexe L1 peuvent-elles causer des cancers ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent un lien entre anomalies immunitaires et risque accru de cancers."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications neurologiques possibles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications neurologiques peuvent survenir, notamment des neuropathies."
}
},
{
"@type": "Question",
"name": "Les complications cardiovasculaires sont-elles possibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications cardiovasculaires peuvent survenir en raison d'inflammations chroniques."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées au complexe L1 ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique un suivi médical régulier et des traitements adaptés aux symptômes."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les anomalies du complexe L1 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des infections chroniques et des facteurs environnementaux."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'anomalies L1 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque peut augmenter avec l'âge en raison de l'affaiblissement du système immunitaire."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur le complexe L1 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut affaiblir le système immunitaire et augmenter le risque d'anomalies."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes augmentent-elles le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes atteintes de maladies auto-immunes ont un risque accru d'anomalies L1."
}
},
{
"@type": "Question",
"name": "L'exposition à des toxines influence-t-elle le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certaines toxines environnementales peut augmenter le risque d'anomalies."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 28/03/2026
Contenu vérifié selon les dernières recommandations médicales
5 publications dans cette catégorie
Publications dans "Complexe antigénique L1 leucocytaire" :
3 publications dans cette catégorie
Affiliations :
The HLA Research Group, Department of Veterans Affairs Health Care System, Brain Sciences Center, Minneapolis VAMC, One Veterans Drive, Minneapolis, MN, 55417, USA.
Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN, USA.
Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN, USA.
Publications dans "Complexe antigénique L1 leucocytaire" :
3 publications dans cette catégorie
Affiliations :
The HLA Research Group, Department of Veterans Affairs Health Care System, Brain Sciences Center, Minneapolis VAMC, One Veterans Drive, Minneapolis, MN, 55417, USA. omega@umn.edu.
Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN, USA. omega@umn.edu.
Institute for Health Informatics, University of Minnesota Medical School, Minneapolis, MN, USA. omega@umn.edu.
Publications dans "Complexe antigénique L1 leucocytaire" :
3 publications dans cette catégorie
Affiliations :
Medicine, Lake Erie College of Osteopathic Medicine (LECOM), Bradenton, USA.
Publications dans "Complexe antigénique L1 leucocytaire" :
2 publications dans cette catégorie
Affiliations :
Institute of Immunology, Department of Pathobiology, University of Veterinary Medicine Vienna, A-1210 Vienna, Austria.
Publications dans "Complexe antigénique L1 leucocytaire" :
2 publications dans cette catégorie
Affiliations :
Department of Biomedical Sciences, BK21 Plus Biomedical Science Project, Seoul National University College of Medicine, Seoul, South Korea. buhm.han@snu.ac.kr.
Department of Convergence Medicine, University of Ulsan College of Medicine & Asan Institute for Life Sciences, Asan Medical Center, Seoul, South Korea. buhm.han@snu.ac.kr.
Interdisciplinary Program for Bioengineering, Seoul National University, Seoul, South Korea. buhm.han@snu.ac.kr.
Publications dans "Complexe antigénique L1 leucocytaire" :
2 publications dans cette catégorie
Publications dans "Complexe antigénique L1 leucocytaire" :
2 publications dans cette catégorie
Affiliations :
Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
Publications dans "Complexe antigénique L1 leucocytaire" :
2 publications dans cette catégorie
Affiliations :
Department of Biomedical Education and Data Science, Lewis Katz School of Medicine, Philadelphia, PA, USA.
Publications dans "Complexe antigénique L1 leucocytaire" :
2 publications dans cette catégorie
Affiliations :
Department of Pathology and Laboratory Medicine, Temple University Hospital, Philadelphia, PA, USA.
Publications dans "Complexe antigénique L1 leucocytaire" :
2 publications dans cette catégorie
Affiliations :
Department of Cardiovascular Surgery, Temple University Hospital, Philadelphia, PA, USA.
Publications dans "Complexe antigénique L1 leucocytaire" :
2 publications dans cette catégorie
Affiliations :
Thalassemia and Hemoglobinopathy Research Center, Research Institute of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Publications dans "Complexe antigénique L1 leucocytaire" :
2 publications dans cette catégorie
Affiliations :
Thalassemia and Hemoglobinopathy Research Center, Research Institute of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Publications dans "Complexe antigénique L1 leucocytaire" :
1 publication dans cette catégorie
Affiliations :
Epidemiology and Public Health Group, University of Exeter Medical School.
Publications dans "Complexe antigénique L1 leucocytaire" :
1 publication dans cette catégorie
Affiliations :
Epidemiology and Public Health Group, University of Exeter Medical School.
Publications dans "Complexe antigénique L1 leucocytaire" :
1 publication dans cette catégorie
Affiliations :
Biostatistics Center, CT Institute for Clinical &Translational Science, Department of Community Medicine and Health Care, University of Connecticut Health Center, Farmington.
Center on Aging, University of Connecticut Health Center, Farmington.
Publications dans "Complexe antigénique L1 leucocytaire" :
1 publication dans cette catégorie
Affiliations :
Center on Aging, University of Connecticut Health Center, Farmington.
Publications dans "Complexe antigénique L1 leucocytaire" :
1 publication dans cette catégorie
Affiliations :
National Institute on Aging, Baltimore, Maryland.
Publications dans "Complexe antigénique L1 leucocytaire" :
1 publication dans cette catégorie
Affiliations :
Epidemiology and Public Health Group, University of Exeter Medical School.
Center on Aging, University of Connecticut Health Center, Farmington.
Publications dans "Complexe antigénique L1 leucocytaire" :
1 publication dans cette catégorie
Affiliations :
Medical Virology Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Publications dans "Complexe antigénique L1 leucocytaire" :
Gynaecological tumours that threaten the health of women, especially when advanced and recurrent, have remained mostly intractable to existing treatments. Therefore, new therapeutic targets are urgent...
KIR3DL1 is a polymorphic inhibitory Natural Killer (NK) cell receptor that recognizes Human Leukocyte Antigen (HLA) class I allotypes that contain the Bw4 motif. Structural analyses have shown that in...
The aim of this study was to determine the Human Leukocyte Antigen (HLA) class II (...
Kaposi sarcoma, caused by the pathogen Kaposi sarcoma-associated herpesvirus (KSHV), is the most common neoplasm for patients with AIDS. Susceptibility to KSHV has been associated with several differe...
A case-control study was performed in Xinjiang, a KSHV-endemic region of China. We recruited 299 individuals with HIV, including 123 KSHV-seropositive persons and 176 KSHV-seronegative controls. We us...
This study provides further insight into the link between...
Antibody-mediated rejection (AMR) is the most common cause of immune-mediated allograft failure after kidney transplant and impacts allograft survival. Previous sensitization is a major risk factor fo...
A 48-year-old, caucasian woman with end-stage kidney disease (ESKD) secondary to autosomal dominant polycystic kidney disease (ADPKD) on peritoneal dialysis was registered in deceased donor waitlist. ...
Shared eplets between the patient husband and donor was responsible for the alloimmune response and early development of DSAs. This case highlights the importance of early monitoring DSA levels in hig...
Dendritic cells (DCs) play a central role in initiating and shaping the adaptive immune response, thanks to their ability to uptake antigens and present them to T cells. Once in the lymph node (LN), D...
Human leukocyte antigen (HLA) sensitization is a major barrier to kidney transplantation induced by exposure to alloantigens through pregnancy, blood product exposure and previous transplantations. De...
Newer desensitization strategies such as imlifidase [immunoglobulin G (IgG) endopeptidase] rapidly inactivates IgG molecules and creates an "antibody-free zone", representing an important advancement ...
Use of these agents alone or in combination will likely improve the efficacy and durability of desensitization therapies, improving access to kidney transplantation for immunologically disadvantaged p...
The development of therapeutics for patients who are positive for specific human leukocyte antigen (HLA) subtypes evokes the question of whether certain racial and ethnic groups are more or less likel...
To determine whether racial and ethnic inequities were present with regard to trial eligibility in trials investigating a therapeutic restricted to patients with specific HLA subtypes....
This cross-sectional study included all clinical trials registered in ClinicalTrials.gov through March 18, 2022, that investigated an interventional study of a therapeutic strategy and restricted part...
The type of therapeutics used in trials, the condition under study, the HLA subtypes used, and the likelihood of being enrolled in such a trial according to race and ethnicity....
Of 2135 trials identified, 263 met inclusion criteria. Overall, the estimated likelihood of being eligible for an HLA-based trial was 50.3%. Individuals of African American descent had the lowest like...
The findings of this cross-sectional study suggest that enrollment restrictions for clinical trials investigating novel HLA therapeutics may be associated with racial and ethnic inequities with regard...
The implementation of highly sensitive immune assays measuring anti-human leukocyte antigen (HLA) antibodies has modified alloimmune risk stratification and diagnosis of rejection. Nonetheless, anti-H...
Functional assays involving ex vivo polyclonal activation of mBC have been refined to allow the detection of HLA-specific mBC capable of producing anti-HLA Abs, using different and complementary detec...
Technological refinements have allowed the development of tests detecting HLA-specific mBC. Further evaluation of these assays in clinical trials, both for immune risk stratification and to assess tre...
Although numerous reports have studied the consequences of human leukocyte antigen (HLA) mismatching in renal transplantation, there are limited and outdated data analyzing this association in thoraci...
We performed a retrospective analysis of adult patients after heart transplant by using the United Network for Organ Sharing database from January 2005-July 2021. Total HLA and HLA-A, HLA-B and HLA-DR...
A total of 33,060 patients were included in this study. Recipients with a high degree of HLA mismatching had increased incidences of acute organ rejection. There were no significant differences in mor...
Our analysis suggests that HLA mismatch is not a significant predictor of survival in the modern era. Overall, the clinical implications of this study provide reassuring data for the continued use of ...